Dabur Pharma announces approval and launch of Irinotecan hydrochloride injection in United States.

Speaking on the occasion, Mr. Ajay Kumar Vij, CEO said "This is a major milestone for Dabur Pharma. This is our 4th product approval in the US market, wherein we have already submitted 13 dossiers. Dabur Pharma is vertically integrated in the product and is already one of the largest producers of Irinotecan API (Active Pharmaceutical Ingredient) in the world. The approval in US will provide a quantum jump to our aggressive growth plans”.

Irinotecan Injection is the generic version of Camptosar®, which had sales of over US$ 556 million in the US (IMS - MAT 03/07). Irinotecan is indicated as a component of first line therapy in combination with 5- fluorouracil and leucovorin for patients with metastatic carcinoma of the colonor rectum. Irinotecan is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil- basedtherapy.

- End -

ABOUT DABUR PHARMA

Dabur Pharma Ltd. is committed to the discovery, development and marketing of drugs that fight cancer. Dedicated to its mission of making cancer therapy available to more and more people, it has been expanding ever since inception. The Company is the leader in the Indian Oncology market and it offers a complete range of products in this segment spanning across Injectables, Orals, Intermediates and APIs and is present in over 40 countries.

For further details, please contact:
Corporate Communications,
Dabur Pharma Limited
PH: 011-30611300 Fax: 011-2619 5907
Priyank Guha @ 9910684895; Kapil Dhawan @ 9810423882